Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc announces CHMP adopts positive opinion for PLEGRIDY as treatment for multiple Sclerosis in European Union


Friday, 23 May 2014 07:59am EDT 

Biogen Idec Inc:Receives positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA).Says for marketing authorization of PLEGRIDY (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis. 

Company Quote

350.6
17.71 +5.32%
2:58pm EST